Related Experiment Videos
The truth is out there: an overall perspective on androgen deprivation
Beth A Hellerstedt1, Kenneth J Pienta
1Division of Hematology/Oncology, University of Michigan Medical Center, 1150 West Medical Center Drive, Box 0640, 5301 MSRB III, Box 0640, Ann Arbor, MI 48109, USA. bhellers@umich.edu
Urologic Oncology
|September 5, 2003
Abstract:
Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.